| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1466252308001527 |
| P698 | PubMed publication ID | 19006597 |
| P2093 | author name string | Gerard D Wright | |
| Patricia L Taylor | |||
| P2860 | cites work | An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis. | Q54466412 |
| Physicochemical properties of antibacterial compounds: implications for drug discovery | Q80662325 | ||
| Discovery of FabH/FabF inhibitors from natural products | Q24538774 | ||
| Lipopolysaccharide endotoxins | Q24650970 | ||
| The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning | Q24652742 | ||
| Essential Bacillus subtilis genes | Q24681292 | ||
| Siderophore-based iron acquisition and pathogen control | Q24681774 | ||
| Structure and function of sedoheptulose-7-phosphate isomerase, a critical enzyme for lipopolysaccharide biosynthesis and a target for antibiotic adjuvants | Q27649206 | ||
| Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa | Q28256421 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis | Q29617342 | ||
| Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 | ||
| High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate | Q33187699 | ||
| Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway | Q33314589 | ||
| Renaissance in antibacterial discovery from actinomycetes | Q33340445 | ||
| A genome-wide strategy for the identification of essential genes in Staphylococcus aureus | Q34123679 | ||
| Novel pathways for biosynthesis of nucleotide-activated glycero-manno-heptose precursors of bacterial glycoproteins and cell surface polysaccharides | Q34137321 | ||
| Bacterial efflux systems and efflux pumps inhibitors | Q34425835 | ||
| Inhibitors of efflux pumps in Gram-negative bacteria | Q34431247 | ||
| Functional analysis of the glycero-manno-heptose 7-phosphate kinase domain from the bifunctional HldE protein, which is involved in ADP-L-glycero-D-manno-heptose biosynthesis | Q34435253 | ||
| Dysregulation of bacterial proteolytic machinery by a new class of antibiotics | Q34456129 | ||
| Natural products to drugs: daptomycin and related lipopeptide antibiotics | Q34470713 | ||
| Isolation and identification of three new 5-alkenyl-3,3(2H)-furanones from two streptomyces species using a genomic screening approach. | Q34530626 | ||
| The therapeutic potential of host-defense antimicrobial peptides | Q34663800 | ||
| eSGA: E. coli synthetic genetic array analysis | Q34803849 | ||
| Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria | Q35010674 | ||
| Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide | Q35077414 | ||
| Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent | Q35630491 | ||
| New targets and screening approaches in antimicrobial drug discovery | Q36034635 | ||
| Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. | Q36373857 | ||
| Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America | Q36382134 | ||
| The biology and future prospects of antivirulence therapies | Q36397902 | ||
| Multidrug-resistance efflux pumps - not just for resistance | Q36538111 | ||
| Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? | Q36550456 | ||
| The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter | Q36550851 | ||
| Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa | Q36593786 | ||
| Tigecycline: a new glycylcycline antimicrobial. | Q36655266 | ||
| Bacterial efflux pump inhibitors from natural sources. | Q36673618 | ||
| Meticillin-resistant Staphylococcus aureus in animals: a review | Q36704113 | ||
| Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy | Q36710571 | ||
| Conclusions: the future of antimicrobial therapy - Augmentin and beyond | Q37009271 | ||
| Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain. | Q37009537 | ||
| Cell-division inhibitors: new insights for future antibiotics | Q37103616 | ||
| Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections | Q37109512 | ||
| Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue | Q37137221 | ||
| Antivirulence as a new antibacterial approach for chemotherapy | Q37221247 | ||
| Platensimycin is a selective FabF inhibitor with potent antibiotic properties | Q38468310 | ||
| Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli | Q41821956 | ||
| A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. | Q41857195 | ||
| Developing a new resource for drug discovery: marine actinomycete bacteria | Q43415262 | ||
| Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens | Q43907044 | ||
| The applications of systematic in-frame, single-gene knockout mutant collection of Escherichia coli K-12. | Q44428947 | ||
| Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay | Q46713387 | ||
| Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. I. Taxonomy, fermentation, isolation and structural elucidation | Q46729565 | ||
| Discovery of a new peptide natural product by Streptomyces coelicolor genome mining | Q46891015 | ||
| Coelichelin, a new peptide siderophore encoded by the Streptomyces coelicolor genome: structure prediction from the sequence of its non-ribosomal peptide synthetase | Q47852288 | ||
| Genomic analyses lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class. | Q48083182 | ||
| A genomics-guided approach for discovering and expressing cryptic metabolic pathways. | Q48264057 | ||
| Marine actinomycetes as a source of novel secondary metabolites. | Q51537343 | ||
| Comparative analysis of essential genes and nonessential genes in Escherichia coli K12. | Q54432611 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 237-246 | |
| P577 | publication date | 2008-11-13 | |
| P1433 | published in | Animal Health Research Reviews | Q15754520 |
| P1476 | title | Novel approaches to discovery of antibacterial agents | |
| P478 | volume | 9 |
| Q47164878 | A half-site multimeric enzyme achieves its cooperativity without conformational changes |
| Q89983811 | Antifungal peptides produced by actinomycetes and their biological activities against plant diseases |
| Q38823840 | Antimicrobial Assessment of Resins from Calophyllum Antillanum and Calophyllum Inophyllum |
| Q26752805 | Bioprospecting Sponge-Associated Microbes for Antimicrobial Compounds |
| Q42618951 | Chemical signaling in the gastrointestinal tract |
| Q35621837 | Development of a novel antimicrobial screening system targeting the pyoverdine-mediated iron acquisition system and xenobiotic efflux pumps. |
| Q33551374 | Evolutionary conservation of essential and highly expressed genes in Pseudomonas aeruginosa |
| Q39264804 | In vitro antimicrobial assessment of Cuban propolis extracts |
| Q50520445 | Potential utility of hyperbaric oxygen therapy and propolis in enhancing the leishmanicidal activity of glucantime. |
| Q35873812 | Unraveling the B. pseudomallei Heptokinase WcbL: From Structure to Drug Discovery |
Search more.